Impact of metabolic syndrome on functional outcomes and complications of surgical treatment of prostate cancer.
impotence
incontinence
metabolic syndrome
prostate cancer
surgical treatment
Journal
Journal of surgical oncology
ISSN: 1096-9098
Titre abrégé: J Surg Oncol
Pays: United States
ID NLM: 0222643
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
received:
01
11
2019
accepted:
04
11
2019
pubmed:
14
11
2019
medline:
4
12
2019
entrez:
14
11
2019
Statut:
ppublish
Résumé
Metabolic syndrome (MetS) has a negative impact on functional recovery and complications after many surgical procedures. To assess the role of Mets on functional outcomes and complications after radical prostatectomy (RP) for prostate cancer. Complete data were collected from 5758 patients, undergoing RP at a single referral centers in a 10-year period and the presence of MetS before surgery was ascertained in 17.7% of them using a modified version of the IDF-AHA/NHLBI criteria. Outcomes included 1-year continence and potency rates, early (≤90 days) and late (>90 days) complications. Postoperative continence (no pads) was significantly less likely in MetS patients (75.4% vs 82.6%, P < .01), despite no difference in preoperative continence. Erections with or without therapy were reached in 55.8% of non-MetS and 41.8% of MetS patients (P < .01), in this case a significant difference in preoperative function was seen. No differences in early and late complications, except for wound infections (5.8% vs 3.9%, P < .01) were observed. In the present study RP was safe from the complications standpoint in MetS patients, but the presence of the syndrome was a significant risk factor for post-RP incontinence and impotence.
Sections du résumé
BACKGROUND
Metabolic syndrome (MetS) has a negative impact on functional recovery and complications after many surgical procedures.
AIM
To assess the role of Mets on functional outcomes and complications after radical prostatectomy (RP) for prostate cancer.
PATIENTS AND METHODS
Complete data were collected from 5758 patients, undergoing RP at a single referral centers in a 10-year period and the presence of MetS before surgery was ascertained in 17.7% of them using a modified version of the IDF-AHA/NHLBI criteria. Outcomes included 1-year continence and potency rates, early (≤90 days) and late (>90 days) complications.
RESULTS
Postoperative continence (no pads) was significantly less likely in MetS patients (75.4% vs 82.6%, P < .01), despite no difference in preoperative continence. Erections with or without therapy were reached in 55.8% of non-MetS and 41.8% of MetS patients (P < .01), in this case a significant difference in preoperative function was seen. No differences in early and late complications, except for wound infections (5.8% vs 3.9%, P < .01) were observed.
CONCLUSIONS
In the present study RP was safe from the complications standpoint in MetS patients, but the presence of the syndrome was a significant risk factor for post-RP incontinence and impotence.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1505-1507Informations de copyright
© 2019 Wiley Periodicals, Inc.
Références
Strom SS, Wang X, Pettaway CA, et al. Obesity, weight gain, and risk of biochemical failure among prostate cancer patients following prostatectomy. Clin Cancer Res. 2005;11:6889-6894. https://doi.org/10.1158/1078-0432.CCR-04-1977
Shiota M, Yokomizo A, Takeuchi A, et al. The feature of metabolic syndrome is a risk factor for biochemical recurrence after radical prostatectomy. J Surg Oncol. 2014;110:476-481. https://doi.org/10.1002/jso.23677
Kwon YS, Leapman M, McBride RB, et al. Robotic-assisted laparoscopic prostatectomy in men with metabolic syndrome. Urol Oncol Seminar Original Invest. 2014;32(40):40.e9-40.e16. https://doi.org/10.1016/j.urolonc.2013.04.008
Jeon KP, Jeong TY, Lee SY, Hwang SW, Shin JH, Kim DS. Prostate cancer in patients with metabolic syndrome is associated with low grade Gleason score when diagnosed on biopsy. Korean J Urol. 2012;53:593-597. https://doi.org/10.4111/kju.2012.53.9.593
Tzimas P, Petrou A, Laou E, Milionis H, Mikhailidis DP, Papadopoulos G. Impact of metabolic syndrome in surgical patients: should we bother? Br J Anaesth. 2015;115:194-202. https://doi.org/10.1093/bja/aev199
Selph JP, Whited WM, Smith AB, et al. Metabolic syndrome as a predictor for postoperative complications after urologic surgery. Urology. 2014;83:1051-1059. https://doi.org/10.1016/j.urology.2014.01.014
Morlacco A, Moro FD, Rangel LJ, Carlson RE, Schulte PJ, Jeffrey KR. Impact of metabolic syndrome on oncologic outcomes at radical prostatectomy. Urol Oncol Seminar Original Invest. 2018;36:528.e1-528.e6. https://doi.org/10.1016/j.urolonc.2018.10.003
Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287:356-359.
Hammarsten J, Peeker R. Urological aspects of the metabolic syndrome. Nat Rev Urol. 2011;8:483-494.
Cantiello F, Cicione A, Salonia A, et al. Metabolic syndrome correlates with peri-urethral fibrosis secondary to chronic prostate inflammation: evidence of a link in a cohort of patients undergoing radical prostatectomy. Int J Urol. 2014;21:264-269. https://doi.org/10.1111/iju.12233